Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
- Sunday, January 23, 2022, 7:10
- PR Newswire
- Add a comment
HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an…
About the Author
admin has written 21717 stories on this site.